Latest Headlines
-
New Drug Candidate Reverses Obesity In Mice
4/30/2024
Researchers at Karolinska Institutet may have found a new way to treat obesity and related disorders by targeting the cells’ powerhouses, the mitochondria.
-
MSD Joins The Open Targets Consortium
4/30/2024
Open Targets, a public-private partnership dedicated to pre-competitive drug discovery research, today announced MSD, the tradename of Merck & Co., Inc., Rahway, N.J., USA, as the latest partner to join the consortium.
-
Scenic Biotech Enters Into Research Collaboration With Bristol Myers Squibb
4/30/2024
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.
-
BigHat Biosciences Enters Into Strategic Collaboration To Leverage Machine Learning In Antibody Discovery & Design
4/24/2024
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company.
-
AI Designs New Drugs Based On Protein Structures
4/24/2024
“It’s a real breakthrough for drug discovery,” says Gisbert Schneider, Professor at ETH Zurich’s Department of Chemistry and Applied Biosciences. Together with his former doctoral student Kenneth Atz, he has developed an algorithm that uses artificial intelligence (AI) to design new active pharmaceutical ingredients.
-
Drug Targeting Clear Cell Renal Cell Carcinoma Shows Promising Approach
4/23/2024
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).
-
A Shortcut For Drug Discovery: Novel Method Predicts On A Large Scale How Small Molecules Interact With Proteins
4/23/2024
For most human proteins, there are no small molecules known to bind them chemically (so called “ligands”). Ligands frequently represent important starting points for drug development but this knowledge gap critically hampers the development of novel medicines.
-
Xaira Therapeutics Launches To Deliver Transformative Medicines By Advancing And Harnessing AI For Drug Discovery And Development
4/23/2024
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
OncoC4 Announces FDA Clearance Of IND Application For Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 For Solid Tumors
4/23/2024
OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced that the United States Food and Drug Administration (“FDA”) has cleared the investigational new drug (“IND”) application for ONC-841, a potential first-in-class SIGLEC 10 blocking antibody for the treatment of solid tumors.
-
Tharimmune Announces Option Agreement For Key Technologies For Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
4/23/2024
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.